187724-61-4

Basic information

• Product Name: PKI 166
• Synonyms: PKI 166;(R)-4-[4-[(1-Phenylethyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenol;(R)-6-(4-Hydroxyphenyl)-4-[(1-phenylethyl)amino]-7H-pyrrolo[2,3-d]pyrimidine;4-[4-(((R)-1-Phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenol;4-[4-[[(1R)-1-Phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-
• CAS NO: 187724-61-4
• Molecular Formula: C₂₀H₁₈N₄O
• Molecular Weight: 330.38312
• Mol File: 187724-61-4.mol
• Article Data: 5

Chemical Properties

• Appearance: white to beige/
• Storage Temp.: 2-8°C
• Solubility: DMSO: soluble10mg/mL, clear
• CAS DataBase Reference: PKI 166(CAS DataBase Reference)
• NIST Chemistry Reference: PKI 166(187724-61-4)
• EPA Substance Registry System: PKI 166(187724-61-4)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 187724-61-4(Hazardous Substances Data)

Upstream product

• 173459-03-5 4-chloro-6-(4-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 3886-69-9 (R)-1-phenyl-ethyl-amine 

Downstream Products

• 1011717-42-2 (R)-2-(4-(4-(1-phenylethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenoxy)acetonitrile 

Relevant articles and documents

Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4- amines as highly potent EGFR-TK inhibitors with Src-family activity

The epidermal growth factor receptor is an important target in molecular cancer therapy. Herein, the enzymatic inhibition potential of a series of chiral and non chiral pyrrolopyrimidine based derivatives have been investigated and optimised. Overall, seven new compounds were identified having enzymatic IC 50 values comparable to or better than the commercial drug Erlotinib. High activity was also confirmed towards the epidermal growth factor receptor L858R and L861Q mutants. Based on calculated druglike properties, eight compounds were further evaluated towards a panel of 52 other kinases revealing interesting Src-family kinase and colony stimulating factor 1 receptor kinase inhibitory activity. Cell proliferation studies with the cell lines A431, C-33A, AU-565, K-562 and genetically engineered Ba/F3-EGFRL858R cells also showed several molecules to be more active than Erlotinib, and thus confirming these pyrrolopyrimidines as attractive drug candidates or lead structures.

FUSED BICYCLIC PYRIMIDINES AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to fused bicyclic pyrimidine containing zinc- binding moiety based derivatives that have unique properties as protein tyrosine kinase (PTK) inhibitors and their use in the treatment of PTK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.

Use of tyrosine kinase inhibitors for the treatment of inflammatory processes

A method of treating inflammatory diseases of the airways or intestines which comprises administering substances selected from the group consisting of: (a) quinazolines of general formula wherein A, B, C, D, X, Ra, Rb, Rc and n are as defined herein, (b) the compounds (1) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-dimethylamino-cyclohexyl)amino]-pyrimido[5,4-d]pyrimidine, (2) 4-[(R)-(1-phenylethyl)amino]-6-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine, and (3) 4-{[3-chloro-4-(3-fluoro-4-benzyloxy)-phenyl]amino}-6-(5-{[(2-methanesulphonyl-ethyl)amino]methyl}-furan-2-yl)quinazoline or (d) the antibodies Cetuximab C225, Trastuzumab, ABX-EGF and Mab ICR-62, and (f) EGFR-antisense.